Embla Medical posted its financial results for the fourth quarter (4Q) and the 2025 fiscal year.
Highlights included:
- Sales amounted to $929 million (USD) compared to $854.9 million in 2024. Organic growth was 6 percent and local currency growth was 7 percent including acquisitions.
- Prosthetics and neuro orthotics sales grew by 10 percent organic, bracing and supports declined 1 percent, and patient care sales grew by 1 percent organic. Growth in 2025 was mainly attributed to strong volume growth and positive product mix supported by high-end solutions.
- Gross profit margin was 62 percent, compared to 63 percent in 2024.
- Earnings before interest, taxes, depreciation, and amortization (EBITDA) margin was 20 percent, on par with 2024.
- Net profit grew by 21 percent and amounted to $84 million or 9 percent of sales, compared to 8 percent of sales in 2024.
- Free cash flow was $100 million or 11 percent of sales, compared to 9 percent of sales in 2024.
- Net-bearing interest debt/EBITDA before special items was 2.4x at the end of 2025, within the company’s target range of 2-3x EBITDA in line with its capital structure and capital allocation policy.
“As we look ahead, we remain confident in our strategy and our ability to navigate change while creating value for patients, customers, employees, healthcare systems, and shareholders. The underlying drivers of demand—an aging population, rising incidence of mobility-limiting conditions, and growing expectations for quality of life, remain firmly in place,” said Sveinn Sölvason president and CEO.
